Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML

Shelley Herbrich, PhD, Natalia Baran, PhDMD, Gheath Alatrash, Eric Davis, MD, Dongxing Zha, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139434

Published: 2020

Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137366

Published: 2020

Journal Articles

Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model

Paul Koller, MD, Karine Harutyunyan, PhD, Antonio Cavazos, MSc, Natalia Baran, PhDMD, Saradhi Mallampati, DVM, PhD, Renee Chin, Zhou Jiang, PhD, Heng-Huan Lee, PhD, Michael Curran, PhD, Mien-Chie Hung, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-141654

Published: 2020

Journal Articles

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Natalia Baran, PhDMD, Alessia Lodi, PhD, Yogesh Dhungana, PhD, Shannon RENEE Sweeney, PhD, Pandey Renu, PhD, Shelley Herbrich, PhD, Fieke W Hoff, BSc, Anna Skwarska, PhD, Mecit Kaplan, MS, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, MSc, Marc Warmoes, PhD, Shanti Rojas-Sutterlin, PhD, Andre Haman, PhD, Diogo Troggian Veiga, PhD, Ken Furudate, DDM, PhD, Helen Ma, MS, Karine Harutyunyan, PhD, Wentao Yang, Mihai Gagea, MDPhD, Di Du, PhD, May Daher, Luciana Melo Garcia, MD, Sujan Piya, PhD, Vivian Ruvolo, MS, Sriram Shanmugavelandy, Ningping Feng, PhD, Jason P Gay, MS, Ondrej Havranek, MDPhD, Jared Henderson, MS, Katarzyna Tomczak, PhD, Marcin Kaminski, PhD, Daniel Herranz, PharmD, Adolfo Ferrando, MD, PhD, Elias Jabbour, MD, Maria E Di Francesco, PhD, David T. Teachey, MD, Terzah M. Horton, MD PhD, Katayoun Rezvani, MD PhD, Jun J. Yang, PhD, Steven M. Kornblau, MD, Eric Davis, MD, Koichi Takahashi, MD PhD, Michael Andreeff, MD PhD, Joseph R Marszalek, PhD, Philip Lorenzi, PhD, Jiyang Yu, PhD, Stefano Tiziani, PhD, Trang Hoang, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-136801

Published: 2020

Journal Articles

Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies

Blood (2019) 134 (Supplement_1): 1936.

https://doi.org/10.1182/blood-2019-126739

Published: 2019

Journal Articles

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Blood (2019) 134 (Supplement_1): 806.

https://doi.org/10.1182/blood-2019-128930

Published: 2019

Journal Articles

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Zhihong Zeng, Natalia Baran, PhDMD, Sergej Konoplev, Antonio Cavazos, Qi Zhang, Vinitha Mary Kuruvilla, MSc, Philip Lorenzi, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Courtney D. DiNardo, MDMSc, Joshua Murtie, Danielle Ulanet, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3911.

https://doi.org/10.1182/blood-2019-125469

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Lina Han, PhD, Antonio Cavazos, Natalia Baran, PhDMD, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Jason P Gay, MS, Ningping Feng, PhD, Venkata Lokesh Battula, PhD, Hagop M. Kantarjian, MD, Naval G. Daver, MD, Joseph R Marszalek, PhD, Michael Andreeff, MD PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 5161.

https://doi.org/10.1182/blood-2019-124475

Published: 2019

Journal Articles

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Blood (2019) 134 (Supplement_1): 911.

https://doi.org/10.1182/blood-2019-125007

Published: 2019

Journal Articles

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Blood (2018) 132 (Supplement 1): 4020.

https://doi.org/10.1182/blood-2018-99-117310

Published: 2018

Journal Articles

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Sujan Piya, PhD, Seemana Bhattacharya, PhD, Hong Mu, MD PhD, Vivian Ruvolo, MS, Natalia Baran, PhDMD, Teresa McQueen, MS, R. Eric Davis, MD, Yimin Qian, PhD, Kanak Raina, PhD, M. James You, MD PhD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD, Gautam Borthakur, MD

Blood (2018) 132 (Supplement 1): 890.

https://doi.org/10.1182/blood-2018-99-115692

Published: 2018

NARROW

Overexpression of CD200 Is a Stem Cell-Specific Mechanism of Immune Escape in AML

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model

Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor

Combining CAR Engineering and CIS Checkpoint Deletion in NK Cells for the Treatment of B Cell Hematologic Malignancies

Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism

Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and i n Vivo

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Mitochondrial Oxphos As Survival Mechanism of Minimal Residual AML Cells after Induction Chemotherapy : Survival Benefit By Complex I Inhibition with Iacs-010759

Oxphos Inhibition Induces Formation of Tunneling Nanotubes in AML Cells and Facilitates Mitochondrial Transfer from BM Stroma to AML That Contributes to Microenvironment-Mediated Drug-Resistance of AML

Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition

Disruption of NOTCH1-MYC-CD44 Axis Targets Leukemia Initiating Cells (LIC) in T-ALL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only